Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

• McCann L,
• Ozdogan H,
• Rutkowska-Sak L,
• Ferrandiz MA,
• Wulffraat NM,
• Brik R,
• Kallinich T,
• Erguven M,
• Berkun Y,
• Constantin T,
• Quartier P,
• Horneff G,
• Brunner H,
• Ruperto N,
• Lheritier K,
• Preiss R,
• Tseng L,
• Martini A,
• Lovell DJ

Affiliations

McCann L

Ozdogan H

Rutkowska-Sak L

Ferrandiz MA

Wulffraat NM

Brik R

Kallinich T

Erguven M

Berkun Y

Constantin T

Quartier P

Horneff G

Brunner H

Ruperto N

Lheritier K

Preiss R

Tseng L

Martini A

Lovell DJ